WUMC-Cancer and Leukemia Group B

简介(摘自申请者摘要)：华盛顿大学自1986年以来一直是CALGB的主要成员机构。在过去的五年里，华盛顿大学医学中心(WUMC)的癌症研究项目经历了巨大的增长。巴恩斯-犹太医院是圣路易斯最大的医院，每年诊断出5400多名癌症患者，仍然是密苏里州东南部和伊利诺伊州南部的主要转诊中心。2001年8月，西门子大学西特曼癌症中心(SCC)获得了NCI指定的癌症中心资格。SCC为成功竞争NCI癌症中心支持补助金而开发的基础设施显著增强了我们开展所有方面的临床癌症研究的能力，包括合作小组试验。我们最近扩大机构研究研究的努力将显著增强我们在下一个赠款周期向CALGB贡献概念的能力，特别是在血液恶性肿瘤、胸部肿瘤学和药物基因组学领域。1998年至2002年，16名华盛顿大学医生和研究助理在36个不同的CALGB科学和行政委员会任职。WUMC调查人员主持了12项CALGB研究，包括非霍奇金淋巴瘤、霍奇金淋巴瘤、前列腺癌、间皮瘤的第二阶段研究，以及几项与药代动力学和药物基因组学相关的科学研究。另外六项研究正处于开发的最后阶段。在这一赠款期间，CALGB试验的应计费用继续增加，从1998年到2001年，平均每年有183名患者登记参加治疗性和非治疗性试验。治疗试验的应计费用从1998年的61名患者增加到2001年的105名。根据到目前为止的登记情况，2002年CALGB试验的预计应计收益估计为312项，其中136项用于治疗研究。下一个资助周期的计划包括1)所有现有WUMC研究人员的继续参与，2)我们第一阶段研究人员的更多参与，以促进CALGB内第二阶段研究的发展，3)至少另外五名WUMC调查人员参与CALGB活动，包括对胃肠道肿瘤学、生活质量、干细胞移植和白血病、白血病相关科学和放射肿瘤学感兴趣的教职员工，以及5)继续努力增加CALGB试验的应计项目，特别是少数应计项目。

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials.